EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (epinephrine) by Baxter International is (α)- and beta (β)-adrenergic receptors. First approved in 2025.
Drug data last refreshed 14h ago · AI intelligence enriched 4d ago
Epinephrine bitartrate in 0.9% sodium chloride is an intravenous solution containing epinephrine, a catecholamine that acts on α- and β-adrenergic receptors to increase cardiac output and peripheral vascular resistance. It is used in acute care settings for hemodynamic support and treatment of anaphylaxis and cardiac arrest. The mechanism involves direct myocardial stimulation, increased heart rate, and peripheral vasoconstriction to elevate blood pressure.
Recent approval (Feb 2025) positions this as an emerging growth product with moderate competitive intensity (30/100); limited current job openings suggest early-stage commercial buildout.
(α)- and beta (β)-adrenergic receptors. The mechanism of the rise in blood pressure is 3-fold: a direct myocardial stimulation that increases the strength of ventricular contraction (positive inotropic action), an increased heart rate (positive chronotropic action), and peripheral vasoconstriction.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements
Worked on EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE at Baxter International? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moThis newly approved IV formulation from Baxter International offers career opportunities in commercializing a critical-care product with established clinical utility but requires navigation of a commodity market with moderate competitive intensity. Career growth will depend on market penetration strategy and Baxter's resource allocation to this product line within emergency/acute care portfolios.